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Aptamers and Possible Effects
on Neurodegeneration
Fatma Söylemez and Çağatay Han Türkseven
Abstract
Aptamers are a new class of recognizing agents which are defined as short
biomolecules like oligonucleotides and peptides that are used in diagnostics and
therapeutics. They can bind to specific targets with extremely high affinity based on
their structural conformations. It is believed that in the near future, aptamers could
replace monoclonal antibody. The biggest advantage of using aptamers is that the
process is in vitro in nature and does not require the use of animals and they also
have unique properties, such as thermal stability, low cost, and unlimited applica-
tions. Aptamers have been studied as a biomaterial in numerous investigations
concerning their use as a diagnostic and therapeutic tool and biosensing probe. DNA
aptamers were also used for the diagnosis and treatment of neurodegeneration and
neurodegenerative diseases. For example, functional nucleic acid aptamers have
been developed to detect Aβ fragments in Alzheimer’s brain hippocampus tissue
samples. Aptamers are promising materials for diverse areas, not just as alternatives
to antibodies but as the core components of medical equipment. Although they are
in the preliminary stages of development, results are quite encouraging, and it
seems that aptamer research has a very bright future in neuroscience.
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1. Introduction
Aptamers, first introduced by Tuerk and Gold and Ellington and Szostak, are
short chains of DNA or RNA oligonucleotides that bind to small molecules, pep-
tides, and macromolecules, such as proteins of various sizes and conformations [1].
Aptamers are oligonucleotides that are possible of targeting specific molecules. The
name aptamer is derived from the Latin word aptus which means to fit. A very
interesting property of aptamers for therapeutic use is the ability of aptamers to
bind with high selectivity. They are small double- or single-stranded DNA or RNA
molecules. Aptamers have been extensively used in basic research, to ensure food
safety and to monitor the environment. Furthermore, aptamers have a promising
role in clinical diagnostics and as therapeutic agents [2].
1.1 Properties of aptamers
Aptamers are short single-chained oligonucleotides that fold into a defined 3D
structure with which they bind specifically and with high affinity to defined target
molecules (Figure 1) [3]. Aptamers usually consist of 15–50 nucleotides and have
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a molecular weight ranging from 5 to 15 kDa [4]. Multiple aptamers have been
generated so far, successfully binding to a wide variety of different objects such as
small molecules, proteins, and cells. Similar to the antibody-antigen interaction, the
recognition between aptamers and their target is very specific.
Recently aptamers are capable of binding different targets such as large protein
complexes, simple inorganic molecules, and total cells [5]. Thus, aptamers can be
regarded as nucleotide analogues of antibodies [6]. However, the production of
aptamers is easier and less expensive than antibodies.
Their binding properties are similar to those found for antibodies, being in the
nanomolar to the picomolar range [7], and aptamers have been identified to distin-
guish between members of a protein family, as they recognize target structures in
an epitope-specific manner [8]. Compared with antibodies, nucleic acid aptamers
have many advantages in their suitability for clinical application and industrializa-
tion, including almost no immunogenicity, efficient penetration, less batch
variation, easy modification, cost-effectiveness, and short production times [9]
(Table 1).
Figure 1.
Schematic representation of binding of an aptamer to a target protein. After binding, the aptamer interacts with
a target molecule such as protein to fold into a 3D structure, which forms a stable target aptamer complex [3].
Table 1.
Comparison between aptamer and antibody.
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1.2 Types of aptamers
Nucleic acid aptamers are short single-stranded DNA or RNA molecules and can
be selected from complex libraries by a technique called “systematic evolution of
ligands by exponential enrichment” (SELEX). These aptamers are capable of bind-
ing to the target molecule with high affinity and specificity. Nucleic acid aptamers
are functionally similar but have some differences in their stability and accessibility
(Table 2). DNA aptamers are less reactive and relatively stable because of the C▬H
bonds at the 21st position of the deoxyribose sugar of DNA nucleotides. This
chemical difference gives DNA aptamers an inherent advantage in stability over
RNA aptamers [10].
RNA aptamers are defined as RNA oligonucleotides that bind to a specific target
with high affinity and specificity, similar to how an antibody binds to an antigen
[11]. RNA aptamers are less stable than DNA aptamers due to the presence of a
reactive hydroxyl group (▬OH) in the 21st position of the ribose sugar in the RNA
nucleotides. This▬OH group is especially deprotonated, particularly in alkali solu-
tions. The resulting anionic 21-O can be nucleophilically attached to the phosphorus
atom of the phosphodiester bond, leading to hydrolysis of RNA molecules. It was
found that the nuclease resistance of RNA aptamers increased when the 21-
hydroxyl group was removed from RNA sugars [10, 12]. Because of the C▬H bonds
of the DNA nucleotides at position 21 of the deoxyribose sugar, DNA aptamers are
less reactive and relatively stable. Due to this chemical difference, DNA aptamers
are more stable than RNA aptamers.
Another type of aptamer developed around 1996 was peptide aptamers. The
concept, originally introduced by Roger Brent, proposed a short amino acid
sequence embedded (“double constrained”) within the context of a small and very
stable protein backbone (“scaffold”) [13, 14]. Peptide aptamers are conjugated
protein molecules with specific binding affinity to target proteins formed under
intracellular conditions. The typical structure of peptide aptamers is a short peptide
region inserted within a scaffold protein. The short peptide region is responsible for
binding with the target protein. The scaffold protein helps to increase binding
affinity and specificity by a restriction on the conformation of the binding peptide
[15]. Thus, peptide aptamer applications range from in vitro detection of various
proteins in a complex mixture to in vivo modulation. In addition, peptide aptamers
Table 2.
Comparison of RNA, DNA, and peptide aptamers.
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have been recognized as therapeutic molecules due to their anticancer and antivirus
activities.
1.3 Aptamer production: selection and identification of aptamers
Aptamers are a new class of recognizing agents that came into light in 1990 [16].
Tuerk and Gold developed a method known as systematic evolution of ligands by
exponential enrichment or popularly called as SELEX method for selection of
aptamers against target [17]. The method is in vitro in nature and does not require
the use of animals. Aptamers are chemically synthesized and selected for their high
affinity and specificity for a certain target through the SELEX process (Figure 2).
The process starts with synthesizing a random DNA oligonucleotide library
(Figure 2). This library consists of a diverse pool of ssDNA fragments (1015). When
selecting RNA aptamers, the library needs to be converted into an RNA library.
Subsequently, the target is introduced in the pool, non-binding fragments are
removed by several washing steps, and the remaining fragments are amplified by
PCR or RT-PCR. A new pool of oligonucleotides is created using the selected
fragments and another round is performed. Usually 8–15 rounds are performed in
order to obtain a high-affinity aptamer.
Figure 2.
Schematic illustration of an in vitro selection cycle.
4
Neuroprotection - New Approaches and Prospects
Since the early 1990s, systematic evolution of ligands by exponential enrichment
and similar methods have been reported to efficiently select RNA and DNA
aptamers [10]. Thereafter, nucleic acid aptamers have been extensively researched
and applied. The identification of aptamers is achieved by an in vitro selection
process, also termed SELEX. In this method, a synthetic nucleic acid library that
contains up to 1015 different sequences and structures is incubated with the desired
target molecule, unbound sequences are removed, and target-linked sequences are
recovered and amplified using PCR or RT-PCR [3, 18]. This cyclic process is
repeated several times (5–16) until the nucleic acid population has been substan-
tially enriched for target-specific sequences. Nucleic acid libraries offer the largest
collection of compounds available so far for screening and selection purposes. The
monoclonal aptamer sequences are accessible by cloning and sequencing these
libraries. But the latest generation sequencing approaches allow in-depth evaluation
of the selection process [19, 20]. A wide range of selection methods and strategies
have been described since the first reports in 1990. The basis of these variations is
based on the separation method used or chemical modifications added to the nucleic
acid libraries.
2. The application of aptamers as molecular tools in neurosciences
Aptamers have a number of diagnostic and therapeutic applications, such as
biosensors and target inhibitors. Due to simple preparation, easy modification, and
stability, aptamers have been used in the diverse areas within molecular biology,
biotechnology, and biomedicine [2]. In general, aptamers are used in diagnostics,
pathogen recognition, cancer recognition, stem cell recognition, monitoring envi-
ronmental contamination, biosensors, and therapeutics. Aptamers are being used in
versatile applications. However, their use as a molecular research tool in neurosci-
ence is limited. There are very few studies on the production of aptamers targeting
neuroscience-related target proteins such as ion channels or application for neuro-
nal cell behavior by inhibiting specific proteins.
Neurodegenerative diseases are defined as hereditary and sporadic conditions
which are characterized by progressive nervous system dysfunction. These disor-
ders are often associated with atrophy of the affected central or peripheral struc-
tures of the nervous system. Alzheimer’s disease (AD) is the most common cause of
dementia and is characterized by progressive loss of memory and other cognitive
functions. It is considered a major epidemic worldwide, where currently more than
35 million people live with this disease. By 2050 it is estimated this figure will reach
115 million [21]. AD is characterized by two major abnormalities; abnormal extra-
cellular amyloid β-protein (Aβ) disposition and intracellular neurofibrillary tangle
(NFT) formation, both leading to neuronal degeneration. The generation of Aβ is
triggered by B-site amyloid precursor protein cleaving enzyme 1 (BACE1). Thus,
BACE1 is a prospective target for interfering with Aβ production and the treatment
of AD [22]. A DNA aptamer selected by Liang et al. has been shown to bind to
BACE1 with high affinity and good specificity, exhibiting a distinct inhibitory effect
on BACE1 activity in an AD cell model [23].
Autoimmunity and autoantibodies play a role in the pathogenesis of many dis-
eases. Recently, a research team in Germany demonstrated the presence of func-
tional autoantibodies against G-protein bound receptors in the serum of Alzheimer’s
and vascular dementia patients [24]. And the aptamer BC007, which is selective for
the GPCR-AAB FAB fragment as a “broad-spectrum neutralizer,” has been devel-
oped based on binding and epitope mapping studies [24]. The fact that BC007
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aptamer was successful in neutralization in an in vitro study revealed the possibility
of being a potential therapeutic tool for dementia patients.
Parkinson’s disease (PD), the second most common neurodegenerative disease
after AD, affects over 7 million people worldwide. The pathology is characterized
by loss of dopaminergic neurons, leading to decreased production of dopamine, a
neurotransmitter that regulates movement and cognition. In the previous immuno-
therapy, targeting the α-syn in PD models with monoclonal antibodies has
established α-syn protein as an effective target for neuronal cell death. The patho-
genesis of Parkinson’s disease involves the accumulation of α-synuclein protein in
neurons. Anti-α-synuclein antibody treatment has achieved some success. How-
ever, this antibody-based immunotherapy is limited by the inherent immunogenic-
ity of antibodies and the inability of antibodies to reach intracellular targets.
To date, there is no recognized cure for Parkinson’s disease. Aptamer-based
immunotherapy is an attractive alternative. Researchers in China have reported
preliminary results for a selective aptamer to α-synuclein. The purified human α-
syn was used as the target for in vitro selection of aptamers using systematic
evolution by exponential enrichment in Zheng et al.’s study [25]. This resulted in
the identification of two 58-base DNA aptamers with a high binding affinity and
good specificity to the α-syn. Both aptamers could effectively reduce α-syn aggre-
gation in vitro and in cells and target the α-syn to intracellular degradation through
the lysosomal pathway. In vitro, the aptamer inhibited the accumulation of α-
synuclein and its association with the mitochondria [26]. It also induced intracellu-
lar α-synuclein degradation, and the neuron maintained viability despite
overexpression of α-synuclein. In vivo, the a-synuclein aptamer can potentially
inhibit the accumulation of a-synuclein in the cell while at the same time promoting
the destruction of existing aggregates and reducing the toxic effects of α-synuclein
aggregates on neurons. These effects consequently rescued the mitochondrial dys-
function and cellular defects caused by α-syn overexpression [26].
Numerous examples in the literature have shown the efficacy of aptamers
against several important targets. Aptamers have been developed to bind to α-
synuclein monomers or its oligomer. These aptamers recognized β-sheet structure,
the moiety though which they can bind not only to α-synuclein oligomer but also Aβ
oligomer. This indicates that these aptamers could also potentially be deployed as
drugs treat Parkinson’s and Alzheimer’s diseases (Figure 3).
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disorder of
the nervous system. Currently, there is no cure for MS, and the available medica-
tions only shorten the duration of attacks to slow the progression of the disease.
Remyelination is a naturally occurring process in the body to restore damaged
myelin sheaths after an MS attack. Rozenblum et al. identified a 40-nucleotide DNA
aptamer which exhibits affinity towards murine myelin and binds to multiple
myelin components in vitro [27]. In mice, it has been shown that aptamer is intro-
duced into CNS tissue by intraperitoneal (IP) injection and dispersed in the tissue
[28]. In addition, the aptamer allowed remyelination of CNS lesions in mice
infected with Theiler virus [29]. Therefore, this aptamer can be used for recovery
following an episode of MS and may alleviate the symptoms of MS.
The toll-like receptor 4 (TLR4) plays a crucial role in the adaptive immune
response. It plays a role in many pathologies including stroke, myocardial infarc-
tion, atherosclerosis, sepsis, multiple sclerosis, and chronic pain. A research group
from Spain investigated TLR4 blocking DNA aptamers, especially for the treatment
of stroke. In an in vivo study involving mice and rats exposed to permanent middle
cerebral artery occlusion (pMCAO), the TLR4-blocking aptamer reduced ischemic
brain injury 4–6 h after injury [30]. The presence of aptamer in the blood and brain
has been demonstrated by imaging studies [30]. Although tissue plasminogen
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activator, tPA, is a viable option in only 5% of stroke treatment cases, TLR4
blocking aptamers have been shown to be a promising and nontoxic alternative.
Signal cascades play an important role in various aspects of cellular homeostasis
and are also connected to several diseases [3, 31]. AMPA receptors are involved in
excitatory synaptic transmission in the CNS and contribute to synaptic plasticity, as it
is known in learning and memory processes [32]. They are hetero-oligomeric pro-
teins, constituted of different combinations of four subunits GluR1-R4. The phos-
phorylation of GluR1 at the amino acid residues Ser831, Ser845, and Ser818 located at
the receptor’s intracellular domain has been found to have a strong impact on AMPA-
mediated neurotransmission. Liu et al. identified an RNA aptamer, termed A2, which
modulates the phosphorylation of the serine residue Ser845 of the GluR1, whereas the
phosphorylation of the Ser831 and Ser818 has been found to be unaffected [33].
Another work identified an RNA aptamer, named C5, which specifically binds and
inhibits the mitogen-activated protein kinase (MAPK) Erk1/2 [34].
Aptamers may be of therapeutic use in treating neurological diseases. One of its
biggest advantages is that aptamers are better able to penetrate tissues, cells, and
blood-brain barrier (BBB) because they are small. They are essentially non-
immunogenic and chemically synthesized. Therefore, they eliminate concerns
about biological contamination or long-term reagent formation that is often
encountered in antibody treatments. Although new drug therapies are a risk to
follow, there is a great potential in terms of increasing survival rates, decreasing
healthcare costs, and high quality of life in aptamers.
Figure 3.
Aptamers targeting α-Syn oligomers for diagnosing and preventing onset of PD and dopamine for diagnosing
dopamine concentrations [26].
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3. Limitations and opportunities of aptamers
Around 50 million people worldwide have Alzheimer’s disease, and more than
10 million people have Parkinson’s disease. The most common type of cancer in
children younger than 19 years is brain tumors and central nervous system tumors
and is the leading cause of cancer-related deaths in children under 14 years of age in
the United States. Although antibody drugs have taken major steps in cancer ther-
apies, the passage of these drugs through the blood-brain barrier and proper
cleansing of the brain limit the use of antibody drugs for the treatment of neuro-
logical diseases.
Aptamers have a number of advantages, such as their high specificity and affin-
ity, their enzymatic or chemical production, and their high reliability and their
renewability in simple ways. Furthermore, they have a higher inhibitory potential
than monoclonal antibodies and have the possibility of wider chemical modification
as they can be synthesized enzymatically or chemically. Aptamers can also remain
stable in a wide variety of buffer environments without loss of activity and are more
resistant to harsh processes such as physical or chemical denaturation. Since
aptamers are developed completely in vitro without the need for cells or animal
immune systems, aptamer production offers a wide variety of binding options.
Aptamers can be produced against a large number of targets, such as molecules that
are toxic to the cell, targets where an immune response does not occur, and com-
pounds that are soluble only in solvents other than water [35]. Given the chemical
and physical properties of aptamers, it is unlikely that they will enter the brain via
paracellular aqueous pathways or transcellular lipophilic pathways. However, the
aptamer may enter the brain by any of the pathways of adsorptive-mediated
transcytosis and channels and/or receptors for absorption or liquid-phase pinocyto-
sis. A recent study has shown that a quadruplex DNA aptamer binds to nucleotide
by micropinocytosis [36]. Cheng et al. identified an aptamer that can enter brain
endothelial cells under physiological conditions, and in vivo, into the brain paren-
chyma [36]. This development has shed light on the use of aptamers in the investi-
gation of neurological diseases.
As all technologies and classes of substances, the use of aptamers has certain
limitations as well as advantages. In vitro selection experiments are the major
obstacle to success, which means whether a specific combination of the target
protein and the nucleic acid library will produce an aptamer. Essentially, this limi-
tation binds to a limited number of nucleotide groups and building blocks from
which a nucleic acid library is made. The four canonical nucleotides, together with
ribose (in the case of RNA) or deoxyribose (in the case of DNA) and phosphate
backbone, are highly limited chemical diversity in comparison to 21 proteinogenic
amino acids that are capable of forming a large number of molecular interactions
and properties such as polar, charged, basic, acidic, aromatic, and aliphatic. There-
fore, the success rate of in vitro selection experiments for protein targets was found
to be 30% [37].
The inability of aptamers to cross cell membranes autonomously (e.g., passive
diffusion represents a further limitation in their applicability and is mainly attributed
to their macromolecules and polyanionic nature). Nevertheless, several options are
available to overcome this restraint (e.g., transfection with liposomes, through plas-
mid or viral delivery or using nanoparticles). In experiments with isolated cells and
cell culture, intracellular distribution of aptamers can be achieved, but this is more
complicated in vivo, especially when the targeted tissue is CNS. The barrier (blood-
brain barrier) cannot passively pass aptamers and other macromolecules. However,
by performing in vivo experiments, aptamers that cross the blood-brain barrier in
mice and penetrate into the brain parenchyma could be identified [36].
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Aptamer technology has emerged into almost every field in the life sciences
since its inauguration 25 years ago. To date, a wide variety of aptamers have been
selected and characterized and also allowed to bind to a wide variety of target
molecules. Aptamers are suitable for diagnostic and therapeutic applications
because of their unique properties. In this chapter, we explained that because of the
specific properties of aptamers, it can be a valuable tool for basic research in the
field of neuroscience. In the future, neurobiology approaches will reveal a number
of interesting target proteins in which specific and potent inhibitors are required.
Analysis of target proteins in neurons and neuronal systems requires identification
and availability of specific inhibitory compounds. Thus, the identification of new
aptamers may be crucial for the timely acquisition of new inhibitors for the treat-
ment of disorders in the neurological system. Together, we believe that aptamers
will be a valuable research tool for neurological studies and that data from new
studies in the field of aptamer and neuroscience will reveal the full potential of
aptamers.
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